Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s): MYCOF

Healthcare Advertising Agencies

Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The Company is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company conducts research and development on second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The Company has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The Company is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.

CSE:MYCO - Post by User

Mydecine Innovations Group Inc

Bullboard Posts

Post by thediggeron Jan 12, 2018 7:25am

64 Views

Post# 27340016

THCX vs NF

I think a partnership could be very beneficial for those 2 companies. I know THCX is far more bigger than NF, but what they would like to do with potentiel new micro producers in Quebec is similar to NF agri-campuses. They could beneficiate NF expertise in this domain. Carman, if you look at this board, you should definitly contact THCX ceo.

Bullboard Posts

Cannara reports record growth and profitability in Q4 2023